Abecma Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Abecma market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to the approval of Abecma for relapsed/refractory multiple myeloma, advancements in CAR T-cell therapy, the rising incidence of multiple myeloma, high efficacy in treatment-resistant cases, and increased investments in research and development.

The projected growth in the forecast period is driven by the rising prevalence of multiple myeloma, expanding approved indications, advances in personalized medicine, global market expansion, and improvements in manufacturing and cost reduction. Key trends in the forecast period include greater adoption in earlier lines of treatment, geographic market expansion, technological advancements in CAR T-cell therapy, combination therapy strategies, personalized and precision medicine, and a growing focus on relapsed/refractory multiple myeloma.

The rise in the prevalence of multiple myeloma is expected to drive the growth of the abecma market. Multiple myeloma is a blood cancer affecting plasma cells in the bone marrow, and its increasing prevalence is linked to an aging population, improved diagnostic techniques, and heightened awareness of the disease. Abecma, a CAR T-cell therapy, offers a novel treatment option by utilizing genetically modified immune cells to target and destroy cancerous plasma cells, particularly in relapsed or refractory cases. According to the American Cancer Society, in January 2024, the projected number of myeloma cases was 35,780, an increase from 34,470 in 2022, highlighting the growing demand for effective treatments like abecma. Therefore, the rise in the prevalence of multiple myeloma is a significant driver for the abecma market.

A key trend in the abecma market is the focus on developing innovative treatments, particularly CAR T-cell therapy, to improve patient outcomes and expand therapeutic options for individuals with relapsed or refractory multiple myeloma. CAR T-cell therapy involves genetically engineering a patient's own T cells to better recognize and destroy cancer cells. In March 2024, Bristol Myers Squibb received European Commission approval for Abecma (idecabtagene vicleucel) to treat adult patients with relapsed and refractory multiple myeloma. This approval specifically targets patients who have undergone at least two prior therapies and have shown disease progression. This marks a major advancement in the treatment landscape for multiple myeloma.

In January 2024, 2Seventy Bio Inc., a US-based biotechnology company, partnered with Bristol Myers Squibb to expand Abecma's growth trajectory. This collaboration aims to increase access to treatment, educate healthcare providers, and potentially broaden Abecma's regulatory indications. This strategic partnership further strengthens the Abecma market, ensuring its position as a leading therapy for multiple myeloma.

Major players operating in the abecma market are Bristol-Myers Squibb.

North America was the largest region in the abecma market in 2024. The regions covered in abecma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the abecma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Abecma (idecabtagene vicleucel) is a CAR T-cell therapy used to treat relapsed or refractory multiple myeloma by targeting and eliminating malignant plasma cells. This therapy involves reprogramming the patient's own immune cells (T cells) to recognize and destroy cancer cells.

The primary indications for abecma are multiple myeloma, B-cell lymphoma (BCL), and acute lymphoblastic leukemia (ALL). Multiple myeloma is a type of blood cancer that begins in the plasma cells, a type of white blood cell in the bone marrow. Abecma is used by various end users, including adults and geriatric populations, and is distributed through several channels, including hospitals, clinics, retail and specialty pharmacies, and online pharmacies.

The abecma market research report is one of a series of new reports that provides abecma market statistics, including abecma industry global market size, regional shares, competitors with an abecma market share, detailed abecma market segments, market trends, and opportunities, and any further data you may need to thrive in the abecma industry. This abecma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The abecma market consists of sales of CAR T-cell therapies, personalized treatments, and immuno-oncology solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.